FMP
NASDAQ
2.39 USD
-0.01 (-0.418%)
Mr. Marc Voigt
Healthcare
Biotechnology
https://www.immutep.com
NASDAQ
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase ...
0001506184
US45257L1089
45257L108
Australia Square
61 2 8315 7003
AU
41
Apr 19, 2012
0001506184
NASDAQ
Biotechnology
Healthcare
45257L108
US45257L1089
AU
2.39
1.81
131.39k
295.41M
-
1.5-3.9
0.05
-
-
-
-
-9.56
-
https://www.immutep.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.